- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00951158
A Molecular Pharmacodynamic Dose-titration Trial of Conjugated Linoleic Acid (CLA; Clarinol®) in Patients With Advanced Solid Tumors
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
New Hampshire
-
Lebanon, New Hampshire, United States, 03756
- Dartmouth-Hitchcock Medical Center, Norris Cotton Cancer Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria
A subject is eligible for inclusion in this study only if all of the following criteria apply:
- Written informed consent.
- Age 18 years or more.
- Performance status of 0, 1, or 2 on the Eastern Co-operative Oncology Group (ECOG) Scale.
- A predicted life expectancy of at least 3 months, in the estimation of the investigator.
- Subjects with histologically or cytologically confirmed advanced solid tumors, who have failed conventional therapy for their tumor type or have a tumor type for which no standard effective therapy exists.
- At least 4 weeks since last chemotherapy, radiotherapy, biologic therapy or surgery. Subjects must be free of post-treatment side effects. No concurrent chemotherapy, biologic therapy or radiotherapy is allowed.
Hematological/clinical chemistry criteria of:
Hemoglobin ≥ 9.0 g/dL WBC ≥ 3,500/mm3 [≥ 3.5 x 109/L] Neutrophils ≥ 1,500/mm3 [≥ 1.5 x 109/L] Platelets ≥ 100,000/mm3 [≥ 100.0 x 109/L] Calculated creatinine clearance ≥60 mL/min using the Cockcroft-Gault Formula.
- Serum bilirubin < 2.0 mg/dL (34 µmol/L)
- SGOT/AST, SGPT/ALT and alkaline phosphatase < 2 times the upper limit of normal if liver metastases cannot be visualized by abdominal computed tomography (CT) or magnetic resonance imaging (MRI scan). If liver metastases are present, subjects with < 5 times the upper limit of normal are eligible to participate.
- Once the RP2D is established, additional patients enrolled at the expanded dose cohort must have tumor that is accessible to two serial biopsies and that is documented (by IHC or RT-PCR) to express S14.
Exclusion Criteria
A subject is ineligible if any of the following criteria apply:
Cancer cachexia, defined by the combination of: unintentional weight loss ≥10%, low
caloric intake (≤ 1500 kcal/day), and systemic inflammation (C-reactive protein ≥ 10mg/L).[52]
- Type II diabetes mellitus
- Women who are pregnant or lactating, or women subjects of childbearing potential who refuse to practice adequate contraception. (oral contraceptives or IUD; double barrier such as diaphragm plus spermicide; vasectomized partner who is sterile prior to the female subject's entry and is the sole sexual partner of that female). Childbearing potential is defined as women who are not surgically sterilized (i.e. have not had a hysterectomy, bilateral oophorectomy [ovariectomy], or bilateral tubal ligation) or post-menopausal (i.e., documented absence of menses for one year prior to entry into the study).
- Men unwilling to abstain from sex or use effective contraception during the study.
- Subjects with uncontrolled emesis, regardless of etiology.
- Active infection, or seropositivity for HIV or Hepatitis B/C.
- Subjects with clinical evidence of any gastrointestinal (GI) conditions (i.e., removal of a portion of the stomach, recent GI obstruction or GI neuropathy) or subjects taking drugs that would alter GI absorption or motility (e.g., cisapride).
- Intercurrent severe medical problems, which would significantly limit full compliance with the study or expose the subject to unnecessary risk.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: CLA
Open-label dose-titration trial of CLA in patients with advanced, refractory malignancies.
oral dose 7.5 g/day 28 day cycle
|
This is a open-label dose-titration trial of CLA in patients with advanced, refractory malignancies. The dose a participant receives is dependent upon the cohort to with the patient is assigned. CLA will be given as oral soft gels, once daily, with pharmacokinetic sampling and biopsies (pretreatment and on day 15). Doses will be escalated by patient cohorts, using an accelerated titration design (single-patient cohorts) with expansion to conventional cohort sizes (3-6 patients) once either inhibition of S14 expression or clinical toxicity is observed. Subjects with stable or responsive disease and who tolerate treatment may continue on CLA until the time of disease progression.
Other Names:
Phase I Dose Escalation Study
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
To define a tolerable dose of oral CLA, given on a daily schedule, that maximally inhibits S14 expression in adipocytes of patients with advanced solid tumors.
Time Frame: 2 years
|
2 years
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
To quantify the effects of CLA on S14 expression in tumor tissue, at its recommended phase II dose
Time Frame: 2 years
|
2 years
|
To quantify effects of CLA on expression of lipogenic enzymes regulated by S14, lipoprotein lipase, and phospho-akt in adipocytes (and tumor tissue).
Time Frame: 2 years
|
2 years
|
To quantify effects of CLA on expression of biomarkers for cellular proliferation, S/G2 phases of cell cycle, and apoptosis in tumor tissue.
Time Frame: 2 years
|
2 years
|
To define the plasma pharmacokinetics of CLA in patients with advanced cancer.
Time Frame: 2 years
|
2 years
|
To obtain data on the safety and tolerability of CLA given orally, on a daily schedule to patients with advanced cancer.
Time Frame: 2 years
|
2 years
|
To document ant tumor activity of CLA, if observed, in this population.
Time Frame: 2 years
|
2 years
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Raymond P Perez, MD, University of Kansas Medical Center
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- D0914
- R21CA131820-01A2 (U.S. NIH Grant/Contract)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Advanced Solid Tumors
-
AmgenCompletedCancer | Advanced Solid Tumors | Solid Tumors | Tumors | Advanced MalignancyUnited States, Australia
-
NantCell, Inc.CompletedQUILT-2.016: Study of AMG 479 With Biologics or Chemotherapy for Subjects With Advanced Solid TumorsCancer | Advanced Solid Tumors | Solid Tumors | Tumors | Advanced Malignancy
-
Incyte CorporationRecruitingA Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid TumorsAdvanced Solid Tumors | Solid Tumors | Metastatic Solid TumorsUnited States, Spain, United Kingdom, France, Italy, Denmark, Switzerland
-
Hoffmann-La RocheCompletedSolid Tumors, Advanced Solid TumorsUnited States
-
Esperance Pharmaceuticals IncCompletedAdvanced Solid Tumors | Solid TumorsUnited States
-
Millennium Pharmaceuticals, Inc.CompletedAdvanced Solid Tumors, Neoplasms, Advanced SolidHungary
-
Incyte Biosciences Japan GKCompletedAdvanced Solid Tumors | Metastatic Solid TumorsJapan
-
Memorial Sloan Kettering Cancer CenterKyowa Hakko Kirin Pharma, Inc.CompletedAdvanced Solid Tumors | Metastatic Solid TumorsUnited States
-
Bristol-Myers SquibbCompletedAdvanced Solid Tumors | Metastatic Solid TumorsKorea, Republic of, Canada, Australia
-
Vividion Therapeutics, Inc.RecruitingAdvanced Solid Tumors | Advanced Hematologic TumorsUnited States, Australia
Clinical Trials on Conjugated Linoleic Acid
-
University of JenaCognis Deutschland GmbH & Co. KGCompleted
-
University of Wisconsin, MadisonCompleted
-
University of Wisconsin, MadisonBunge Loders CroklaanCompleted
-
University of North CarolinaCognisCompleted
-
Ohio State UniversityCognisCompleted
-
Dartmouth-Hitchcock Medical CenterDartmouth CollegeCompleted
-
Hamilton Health Sciences CorporationCompleted
-
University of ChesterCompletedInflammation | Obesity | Lipid Disorder | Lung FunctionsUnited Kingdom
-
Universidade Federal do Rio de JaneiroRio de Janeiro State Research Supporting Foundation (FAPERJ)CompletedInsulin Resistance | Blood Pressure | Oxidative Stress | Lipid Profile | Anthropometric MeasureBrazil
-
Washington University School of MedicineBASFCompleted